---
layout: default
title: Benzoic Acid
parent: 僅模型預測 (L5)
nav_order: 98
evidence_level: L5
indication_count: 10
---

# Benzoic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Benzoic Acid: From Antifungal Agent to Bronchitis

## One-Sentence Summary

Benzoic acid is a well-known antimicrobial compound with historical use as an antifungal agent, preservative, and respiratory expectorant (via Tincture of Benzoin), with no currently registered drug products in India.
The TxGNN model predicts it may be effective for **Bronchitis**, with **0 clinical trials** and **2 publications** currently supporting this direction.
Importantly, neither publication directly establishes benzoic acid's therapeutic activity against bronchitis, and the mechanistic link remains unverified.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indications registered in India (historically used as antifungal agent and respiratory expectorant) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for benzoic acid. Based on known historical and pharmacological information, benzoic acid is a simple aromatic carboxylic acid with documented antimicrobial and antifungal properties. Tincture of Benzoin (a benzoin resin compound containing benzoic acid derivatives) has been used historically as an inhalant expectorant to relieve coughs and upper airway inflammation, which provides a plausible historical link to respiratory indications such as bronchitis.

The TxGNN prediction likely exploits two indirect graph paths in the knowledge graph: (1) benzoic acid's structural presence as a core scaffold in benzoic acid derivative drugs (e.g., repaglinide, a carbamoylmethyl benzoic acid derivative), and (2) a potential anti-inflammatory/antioxidant pathway suggested by soluble epoxide hydrolase (sEH) inhibitor research in smoke-induced COPD. However, the available literature does not directly confirm that benzoic acid itself possesses sEH-inhibitory activity.

The mechanistic hypothesis — benzoic acid → antimicrobial/anti-inflammatory activity → bronchitis symptom relief — is biologically plausible at the conceptual level but lacks any direct experimental or clinical validation. The prediction should be treated as a hypothesis-generating signal only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|-------------|
| [22180869](https://pubmed.ncbi.nlm.nih.gov/22180869/) | 2012 | Preclinical/Animal Study | Am J Respir Cell Mol Biol | sEH inhibitors showed anti-inflammatory effects in a rat model of tobacco smoke-induced COPD (which includes bronchitis component); benzoic acid's direct sEH-inhibitory activity is not established |
| [11577798](https://pubmed.ncbi.nlm.nih.gov/11577798/) | 2001 | Review | Drugs | Review of repaglinide — a carbamoylmethyl benzoic acid derivative — for type 2 diabetes; relevant as structural context only, no direct bronchitis evidence |

> **Note:** Neither publication directly investigates benzoic acid in bronchitis. Relevance is indirect (structural scaffold reference and respiratory disease model). These citations were retrieved by keyword association and do not constitute primary evidence for this repurposing hypothesis.

---

## India Market Information

Benzoic acid (DrugBank ID: DB03793) has **no registered drug products** in India. It is not marketed as a standalone pharmaceutical agent in India's regulatory database.

---

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction data, key warnings, or contraindication data were available from the data sources queried for this report.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence level is L5 (model prediction only, no clinical studies), and neither of the two retrieved publications provides direct evidence that benzoic acid is effective for bronchitis. The mechanistic link is speculative, and benzoic acid has no regulatory approval in India for any indication.

**To proceed, the following is needed:**

- **MOA verification:** Confirm whether benzoic acid or its metabolites (hippuric acid, benzoyl-CoA) have measurable anti-inflammatory or antimicrobial activity relevant to bronchial epithelium
- **sEH inhibitory activity assay:** In vitro testing of benzoic acid for soluble epoxide hydrolase inhibition to test the primary mechanistic hypothesis
- **Safety profiling:** Retrieve CDSCO/full prescribing information and systemic toxicity data (high-dose benzoic acid is associated with irritation, metabolic acidosis in certain populations)
- **Formulation feasibility:** Assess whether an inhalation or oral formulation of benzoic acid can achieve therapeutic concentrations in the bronchial mucosa without toxicity
- **Preclinical bronchitis model:** Conduct a focused in vivo study in a lipopolysaccharide (LPS)- or smoke-induced bronchitis animal model before any clinical planning
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

